Feb 6, 2026
9:24 AM9:33 AM
Main Session
Subcutaneous Four-Week Dosing of the Novel Protein S Antibody VGA039 Demonstrates Safety and Clinically Meaningful Bleed Reduction in Patients with Von Willebrand Disease: Phase 1/2 Multi-Dose Study Results
Gabriela Yamaguti-Hayakawa